### Supplemental Table S1: Inclusion and exclusion criteria

Every patient has to fulfill the following **inclusion criteria**:

- patients with a diagnosis of a chronic inflammatory rheumatic disease
- patients who have/had already a glucocorticoid therapy, or patients in which the implementation of a new long-term GC therapy is expected
- patients who, according to the DVO guidelines (see Supplemental Box 2), attend our osteoporosis and bone metabolism outpatient consultation hours or are referred by the hospital wards of the Charité for diagnosis, treatment or follow-up
- capability to understand the patient information
- consent to participation in the project and storage of data

If any of the following **exclusion criteria** is true, the patient must not be included in this study:

- postmenopausal women without an inflammatory rheumatic disease
- alcohol, medication and/or drug addiction
- severe psychiatric diseases limiting the comprehension of the project plan and the study protocol (persons incapable of giving informed consent)
- pregnant and lactating patients
- patients incapable of giving informed consent for any reason
- prisoners and all persons who are committed to an institution due to an official or judicial order
Supplemental Table S2: Medically pre-selected variables considered for the linear regression model on T-scores. Variables excluded from analysis due to >30% missing values are shown in italic font; exceptions were ALT (31.0% missings), alkaline phosphatase (32.1%), and deoxypyridinoline (34.0%). Disease specific scores were only included for subgroup analyses of RA patients.

| Level of agreement | valid | |
|--------------------|-------|---|
| known              |       |   |
| Age at inclusion   | 1066  | 100.0 |
| Sex                | 1066  | 100.0 |
| BMI                | 1066  | 100.0 |
| Bisphosphonate     | 1066  | 100.0 |
| Teriparatide       | 1066  | 100.0 |
| Denosumab          | 1066  | 100.0 |
| Menopause          | 1058  | 99.2 |
| highly expected    |       |   |
| GC current         | 1066  | 100.0 |
| GC duration (years)| 868   | 81.4 |
| GC, cumulative dose (g)| 928  | 87.1 |
| disease duration (years) | 1046 | 98.1 |
| CDAI* (only RA)    | 72    | 16.6 |
| DAS28(ESR)* (only RA) | 245  | 56.5 |
| DAS28(CRP)* (only RA) | 402  | 92.6 |
| SDAI* (only RA)    | 68    | 15.7 |
| NSAIDs             | 1066  | 100.0 |
| bDMARD             | 1066  | 100.0 |
| csDMARD            | 1066  | 100.0 |
| tsDMARDs           | 1066  | 100.0 |
| need for low level care support | 933  | 87.5 |
| Family history of osteoporosis | 776  | 72.8 |
| Family history of osteoporotic fractures | 766  | 71.9 |
| Vitamin D supplementation | 1066 | 100.0 |
| Daily calcium intake | 1055 | 99.0 |
| Alcohol intake     | 1051  | 98.6 |
| Smoking            | 1058  | 99.2 |
| Smoking, pack-years| 932   | 87.4 |
| Sun exposure       | 1052  | 98.7 |
| History of recurrent falls | 1061 | 99.5 |
| Vertebral (low impact) fractures | 1066 | 100.0 |
| Non-vertebral (low impact) fractures | 1066 | 100.0 |
| 25(OH)VitD (nmol/l) | 943   | 88.5 |
| Vitamin D deficiency (<50 nmol/L) | 943  | 88.5 |
| HAQ                | 1028  | 96.4 |
| weakly expected | CRP (mg/l) | 926 | 86.9 |
|----------------|-----------|-----|------|
| PPI            | 1066      | 100.0 |
| Antidiabetics  | 1066      | 100.0 |
| Folic acid     | 1066      | 100.0 |
| Antidepressants| 1066      | 100.0 |
| L-thyroxine    | 1066      | 100.0 |
| Renal insufficiency | 1066    | 100.0 |
| Diabetes mellitus (type I or II) | 1066 | 100.0 |
| Gout/ hyperuricaemia | 1066 | 100.0 |
| Hyperthyroidism| 1066      | 100.0 |
| Calcium supplementation | 1066 | 100.0 |
| Bone specific alkaline phosphatase (ug/l) | 734 | 68.9 |
| Osteocalcin (ng/ml) | 527 | 49.4 |
| Parathyroid hormone (ng/l) | 897 | 84.1 |
| Urinary deoxy pyridinoline (nmol/l) | 704 | 66.0 |
| Chloride (mmol/l) | 236 | 22.1 |
| Alkaline phosphatase (U/l) | 724 | 67.9 |
| ALT (U/l) | 736 | 69.0 |
| AST (U/l) | 696 | 65.3 |
| Phosphate (mmol/l) | 336 | 31.5 |
| ESR (mm/h) | 391 | 36.7 |
| Calcium (mmol/l) | 989 | 92.8 |
| Gamma-GT (U/l) | 791 | 74.2 |
| Uric acid (mg/dl) | 458 | 43.0 |
| Creatinine (Jaffe) (mg/dl) | 995 | 93.3 |
| Regular physical exercise | 1041 | 97.7 |
| ACPA* (only RA) | 306 | 70.5 |

* RA-specific activity scores/ biomarker were only considered for RA patients.

BMI body mass index; GC glucocorticoids; RA rheumatoid arthritis; CDAI clinical disease activity index; DAS28 disease activity score-28; ESR erythrocyte sedimentation rate; NSAIDs non-steroidal anti-inflammatory drugs; bDMARD biological disease-modifying antirheumatic drugs; csDMARD conventional synthetic disease-modifying antirheumatic drugs; tsDMARD targeted synthetic disease-modifying antirheumatic drugs; HAQ health assessment questionnaire; CRP C-reactive protein; PPI proton-pump inhibitors; ALT alanine aminotransferase; AST aspartate aminotransferase; Gamma-GT gamma-glutamyltransferase; ACPA anti-citrullinated protein antibody
Supplemental Table S3: The impact of seropositivity for anti-citrullinated protein antibody (ACPA)/rheumatoid factor (RF) on bone mineral density (BMD; given as lowest (minimum = min.) T-Score) in multivariable linear regression models for RA patients described as four combinations: i) positive ACPA status, ii) positive RF status, defined as either IgA or IgM positivity; iii) double positive, defined as both positive ACPA and RF status; and iv) double negative, defined as both negative ACPA and RF status. Shown are regression coefficients \( \beta \) and respective 95% confidence intervals.

| All patients | Min. T-Score | Min. lumbar T-Score | Min. T-Score femoral neck |
|--------------|--------------|---------------------|--------------------------|
|              | Reg. coefficient (95%CI) | \( p \)-value | Reg. coefficient (95%CI) | \( p \)-value | Reg. coefficient (95%CI) | \( p \)-value |
| ACPA positive| 0.064 (-0.259;0.386) | 0.696 | 0.147 (-0.315;0.608) | 0.531 | 0.096 (-0.186;0.378) | 0.503 |
| RF positive  | -0.026 (-0.353;0.301) | 0.873 | -0.057 (-0.580;0.465) | 0.826 | 0.002 (-0.285;0.288) | 0.992 |
| Double positive| -0.009 (-0.296;0.277) | 0.948 | 0.083 (-0.389;0.554) | 0.726 | 0.013 (-0.252;0.278) | 0.922 |
| Double negative| -0.074 (-0.524;0.376) | 0.741 | 0.030 (-0.559;0.618) | 0.920 | -0.121 (-0.476;0.233) | 0.500 |
Supplemental Table S4: Multivariable linear regression. Factors are sorted by descending number and then average strength of association. Variables with at least one significant impact in multivariable linear regression of the lowest (minimum = min.) T-Score at I) any site, II) lumbar spine (L1-L4) and III) right and left femoral neck in a) all patients and b) in patients with RA. c) lists results of a sensitivity analysis excluding patients on specific antiosteoporosis drugs (bisphosphonates and denosumab). Shown are regression coefficients $\beta$ and respective 95% confidence intervals. Significant impact factors are highlighted in bold. For a complete set of considered variables see Supplemental Table S2.

|                      | I) Min. T-Score | II) Min. lumbar T-Score | III) Min. T-Score femoral neck |
|----------------------|-----------------|--------------------------|-------------------------------|
|                      | Reg. coefficient (95%CI) | $p$-value | Reg. coefficient (95%CI) | $p$-value | Reg. coefficient (95%CI) | $p$-value |
| BMJ                  | 0.070 (0.058;0.082) | $<0.001$ | 0.067 (0.049;0.085) | $<0.001$ | 0.069 (0.057;0.081) | $<0.001$ |
| Bisphosphonates      | $-0.451$ (-0.644;−0.258) | $<0.001$ | $-0.490$ (-0.774;−0.206) | 0.001 | $-0.415$ (-0.605;−0.224) | $<0.001$ |
| Alkaline phosphatase (Units/l) | $-0.005$ (-0.008;−0.002) | 0.001 | $-0.008$ (-0.012;−0.004) | $<0.001$ | $-0.004$ (-0.007;−0.002) | 0.002 |
| Menopause            | $-0.436$ (-0.696;−0.177) | 0.001 | $-0.555$ (-0.925;−0.185) | 0.003 | $-0.349$ (-0.599;−0.100) | 0.006 |
| Proton pump inhibitors | $-0.179$ (-0.304;−0.054) | 0.005 | $-0.342$ (-0.525;−0.159) | $<0.001$ | $-0.138$ (-0.260;−0.016) | 0.027 |
| Gamma--GT (Units/l) | 0.002 (0.001;0.004) | 0.007 | 0.003 (0.001;0.005) | 0.015 | 0.002 (0.000;0.004) | 0.033 |
| Age (years)          | $-0.012$ (-0.018;−0.006) | $<0.001$ | $-0.007$ (-0.016;0.001) | 0.097 | $-0.015$ (-0.021;−0.009) | $<0.001$ |
| Male sex             | $-0.447$ (-0.726;−0.169) | 0.002 | $-0.222$ (-0.619;0.175) | 0.273 | $-0.445$ (-0.713;−0.176) | 0.001 |
| Current GC dose (mg/day) | 0.003 (0.001;0.005) | 0.004 | 0.001 (-0.002;0.004) | 0.382 | 0.003 (0.001;0.005) | 0.006 |
| HAQ--Score           | $-0.126$ (-0.226;−0.026) | 0.014 | $-0.065$ (-0.215;0.086) | 0.399 | $-0.165$ (-0.264;−0.066) | 0.001 |
| NSAIDs               | 0.013 (-0.033;0.259) | 0.130 | 0.175 (-0.038;0.387) | 0.107 | 0.181 (0.038;0.324) | 0.013 |
| Denosumab            | $-0.417$ (-0.784;−0.051) | 0.026 | $-0.421$ (-0.960;0.118) | 0.126 | $-0.219$ (-0.574;0.137) | 0.228 |
| Current GC dose ≥5mg/day | $-0.093$ (-0.224;0.038) | 0.162 | $-0.105$ (-0.296;0.086) | 0.281 | $-0.129$ (-0.257;−0.001) | 0.049 |
| Prior non–vertebral fracture | $-0.427$ (-0.903;0.050) | 0.079 | 0.200 (-0.508;0.909) | 0.580 | $-0.526$ (-0.990;−0.063) | 0.026 |
| Prior vertebral fracture | $-0.393$ (-0.773;−0.012) | 0.043 | 0.008 (-0.534;0.549) | 0.978 | $-0.340$ (-0.709;0.029) | 0.071 |
| Diabetes (Type I or II) | 0.103 (-0.150;0.355) | 0.426 | 0.411 (0.031;0.791) | 0.034 | $-0.027$ (-0.274;0.220) | 0.830 |
| Calcium supplementation | $-0.089$ (-0.370;0.193) | 0.537 | $-0.457$ (-0.858;−0.056) | 0.026 | 0.028 (-0.249;0.305) | 0.843 |
| Sun exposure (>30 min/day) | 0.034 (-0.090;0.159) | 0.591 | 0.027 (-0.155;0.210) | 0.768 | 0.122 (0.001;0.242) | 0.048 |
### b) RA patients

|                        | I) Min. T-Score        | II) Min. lumbar T-Score | III) Min. T-Score femoral neck |
|------------------------|------------------------|-------------------------|---------------------------------|
|                        | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value |
| BMI                    | 0.054 (0.035;0.073)     | <0.001     | 0.044 (0.014;0.074)     | 0.004    | 0.057 (0.038;0.076)     | <0.001  |
| Alkaline phosphatase (U/l) | -0.004 (−0.008;0.000) | 0.041     | -0.007 (−0.013;0.000)   | 0.039    | -0.005 (−0.009;−0.001)  | 0.022   |
| Age (years)            | -0.025 (−0.036;−0.014)  | <0.001     | -0.016 (−0.032;0.001)   | 0.065    | -0.028 (−0.039;−0.018)  | <0.001  |
| Current GC dose > 5 mg/day | -0.487 (−0.850;−0.124) | 0.009     | -0.772 (−1.314;−0.230)  | 0.005    | -0.332 (−0.677;0.014)   | 0.060   |
| Male sex               | -0.582 (−1.072;−0.093)  | 0.020     | -0.709 (−1.446;0.029)   | 0.060    | -0.526 (−0.990;−0.062)  | 0.026   |
| Menopause              | -0.546 (−1.000;−0.091)  | 0.019     | -0.958 (−1.634;−0.283)  | 0.005    | -0.302 (−0.731;0.126)   | 0.167   |
| Bisphosphonates        | -0.405 (−0.697;−0.113)  | 0.007     | -0.298 (−0.758;0.162)   | 0.204    | -0.414 (−0.698;−0.131)  | 0.004   |
| Disease duration (years) | 0.017 (0.002;0.032)   | 0.030     | 0.014 (−0.009;0.037)    | 0.223    | 0.014 (−0.001;0.029)    | 0.062   |
| Sun exposure (>30 min/day) | 0.166 (−0.031;0.364)  | 0.098     | 0.146 (−0.159;0.452)    | 0.348    | 0.219 (0.031;0.406)     | 0.022   |
| Teriparatide           | -1.242 (−2.729;0.244)  | 0.101     | -1.028 (−3.246;1.191)   | 0.364    | -1.514 (−2.931;−0.097)  | 0.036   |
| CRP (mg/l)             | -0.008 (−0.017;0.000)  | 0.051     | -0.005 (−0.018;0.008)   | 0.474    | -0.008 (−0.016;0.000)   | 0.050   |
| Denosumab              | -0.626 (−1.220;−0.032) | 0.039     | -0.466 (−1.401;0.468)   | 0.328    | -0.324 (−0.892;0.244)   | 0.263   |
### c) Sensitivity analysis: Exclusion of patients with denosumab, bisphosphonates or teriparatide.

| All patients (after exclusion of patients with denosumab, bisphosphonates or teriparatide) | I) Min. T-Score | II) Min. lumbar T-Score | III) Min. T-Score femoral neck |
|---|---|---|---|
| | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value |
| BMI | 0.073 (0.060;0.086) | <0.001 | 0.069 (0.051;0.088) | <0.001 | 0.070 (0.057;0.083) | <0.001 |
| Age (years) | −0.012 (−0.019;−0.005) | <0.001 | −0.007 (−0.017;0.002) | 0.132 | −0.015 (−0.021;−0.008) | <0.001 |
| Menopause | −0.481 (−0.755;−0.208) | 0.001 | −0.620 (−1.000;−0.239) | 0.001 | −0.408 (−0.675;−0.142) | 0.003 |
| Prior vertebral fracture | −0.848 (−1.384;−0.312) | 0.002 | −0.848 (−1.586;−0.110) | 0.024 | −0.642 (−1.165;−0.119) | 0.016 |
| Male sex | −0.463 (−0.757;−0.170) | 0.002 | −0.279 (−0.690;0.132) | 0.183 | −0.467 (−0.754;−0.181) | 0.001 |
| Alkaline phosphatase (Units/l) | −0.005 (−0.008;−0.001) | 0.005 | −0.007 (−0.011;−0.003) | <0.001 | −0.004 (−0.007;−0.001) | 0.007 |
| Current GC dose (mg/day) | 0.003 (0.001;0.005) | 0.007 | 0.001 (−0.002;0.004) | 0.539 | 0.003 (0.001;0.005) | 0.006 |
| Proton pump inhibitors | −0.173 (−0.311;−0.036) | 0.013 | −0.338 (−0.536;−0.140) | 0.001 | −0.134 (−0.269;0.001) | 0.051 |
| Gamma–GT (Units/l) | 0.002 (0.000;0.004) | 0.027 | 0.002 (0.000;0.005) | 0.066 | 0.002 (0.000;0.003) | 0.055 |
| Calcium supplementation | −0.560 (−1.091;−0.028) | 0.039 | −0.662 (−1.424;0.100) | 0.089 | −0.570 (−1.097;−0.044) | 0.034 |
| Current GC dose ≥ 5mg/day | −0.138 (−0.284;0.007) | 0.063 | −0.090 (−0.299;0.118) | 0.394 | −0.153 (−0.296;−0.010) | 0.036 |
| HAQ–Score | −0.102 (−0.216;0.011) | 0.077 | −0.095 (−0.259;0.070) | 0.258 | −0.147 (−0.260;−0.034) | 0.011 |
| NSAIDs | 0.098 (0.059;0.255) | 0.223 | 0.167 (0.056;0.391) | 0.143 | 0.168 (0.014;0.323) | 0.033 |
| Sun exposure (>30 min/day) | 0.079 (0.057;0.214) | 0.254 | 0.064 (−0.130;0.257) | 0.518 | 0.146 (0.014;0.278) | 0.030 |
| Diabetes (Type I or II) | 0.104 (−0.185;0.394) | 0.480 | 0.478 (0.059;0.897) | 0.025 | −0.062 (−0.348;0.224) | 0.669 |
Supplemental Table S5: Multivariable linear regression with backward selection on the variables which have emerged from the data mining regression for the three T-scores (compare Supplemental Table S4a). Coefficients of the variables which were selected into the respective model are highlighted in bold font; only diabetes and calcium supplementation were not confirmed for the lumbar T-score model.

| All patients | I) Min. T-Score | II) Min. lumbar T-Score | III) Min. T-Score femoral neck |
|--------------|----------------|-------------------------|-------------------------------|
|              | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value | Reg. coefficient (95%CI) | p-value |
| BMI          | 0.071 (0.060;0.082) | <0.001 | 0.066 (0.050;0.082) | <0.001 | 0.072 (0.061;0.083) | <0.001 |
| Bisphosphonates | -0.463 (-0.652;-0.275) | <0.001 | -0.561 (-0.830;-0.292) | <0.001 | -0.390 (-0.572;-0.207) | <0.001 |
| Alkaline phosphatase (Units/l) | -0.005 (-0.008;-0.002) | <0.001 | -0.007 (-0.010;-0.003) | <0.001 | -0.004 (-0.007;-0.002) | 0.001 |
| Menopause    | -0.440 (-0.688;-0.192) | 0.001 | -0.542 (-0.724;-0.359) | <0.001 | -0.370 (-0.610;-0.131) | 0.002 |
| Proton pump inhibitors | -0.221 (-0.341;-0.101) | <0.001 | -0.375 (-0.546;-0.203) | <0.001 | -0.148 (-0.267;-0.030) | 0.014 |
| Gamma-GT (Units/l) | 0.002 (0.001;0.004) | 0.005 | 0.002 (0.000;0.005) | 0.027 | 0.002 (0.000;0.004) | 0.012 |
| Age (years)  | -0.012 (-0.018;-0.007) | <0.001 | -0.017 (-0.022;-0.012) | <0.001 | -0.017 (-0.022;-0.012) | <0.001 |
| Male sex     | -0.413 (-0.674;-0.152) | 0.002 | -0.435 (-0.687;-0.183) | 0.001 | -0.435 (-0.687;-0.183) | 0.001 |
| Current GC dose (mg/day) | 0.002 (0.000;0.004) | 0.005 | 0.003 (0.001;0.005) | 0.002 | 0.003 (0.001;0.005) | 0.002 |
| HAQ–Score    | -0.137 (-0.217;-0.058) | 0.001 | -0.196 (-0.277;-0.115) | <0.001 | -0.196 (-0.277;-0.115) | <0.001 |
| NSAIDs       | 0.190 (0.053;0.327) | 0.007 | 0.190 (0.053;0.327) | 0.007 | 0.190 (0.053;0.327) | 0.007 |
| Denosumab    | -0.537 (-0.895;-0.179) | 0.003 | -0.144 (-0.266;-0.023) | 0.020 | -0.144 (-0.266;-0.023) | 0.020 |
| Current GC dose ≥5mg/day | -0.322 [-0.573;0.072] | 0.012 | -0.232 [-0.360;0.104] | <0.001 | -0.232 [-0.360;0.104] | <0.001 |
| Prior non–vertebral fracture | 0.215 (-0.054;0.484) | 0.118 | 0.215 [-0.054;0.484] | 0.118 | 0.215 [-0.054;0.484] | 0.118 |
| Prior vertebral fracture | -0.006 (-0.177;0.165) | 0.946 | -0.006 (-0.177;0.165) | 0.946 | -0.006 (-0.177;0.165) | 0.946 |
| Diabetes (Type I or II) | 0.142 (0.027;0.256) | 0.015 | 0.142 (0.027;0.256) | 0.015 | 0.142 (0.027;0.256) | 0.015 |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental Box S1

Why are anti-inflammatory effects of low-dose glucocorticoids suggested to compensate – at least in part – for their detrimental effects on bone mineral density in patients with rheumatoid arthritis?

1. There is no doubt that glucocorticoids applied in higher doses and for a longer time have deleterious effects on bone (Buttgereit, Nat Rev Rheum (2020); Rizzoli et al. Nat Rev Rheum (2015). They certainly can induce early and sometimes rapid bone loss which increases fracture risk.

2. Equally well known, however, is the fact that inflammation promotes bone resorption (Hardy and Cooper, J. Endocrinol 2009). Therefore, inflammation associated with iRMDs is an important determinant of bone fragility, as well (Briot et al., Osteoporos. Int. (2017); Ozen et al. Ann. Rheum. Dis. (2019).

3. Excellent publications have recently reviewed the body of evidence how inflammation mechanistically skews the process of bone remodeling toward resorption. (Briot et al. Osteoporosis Int. 2017; Epsley et al. Front Physiol, 2021). The main message is that inflammatory mediators (including TNFα, interleukins 1 and 6) and their related peptides interact with osteoblasts, osteoclasts, and other immune cells to alter the expression of RANK and RANKL.

4. In rheumatoid arthritis, synovial macrophages produce inflammatory cytokines such as TNF-α, IL-1, and IL-6 which induce bone resorption, partly via increasing RANKL. Furthermore, RANKL is expressed in RA synovial fibroblasts, thereby promoting differentiation of synovial macrophages into osteoclasts (Epsley et al. Front Physiol, 2021; Bruno et al. Front Med, 2021; Llorente et al. Front Med, 2021).

5. Glucocorticoids – used in synergy with DMARDs - are capable of inducing strong immunosuppressive and anti-inflammatory on immune cells, tissues and organs (Strehl, Buttgereit et al. Front Immunology, 2019). An important underlying mechanism for these effects is that glucocorticoids influence cytokine production. In this context, it is well known that they reduce inflammation by downregulating the synthesis of proinflammatory mediators such as TNF-α, IL-1, and IL-6. (Stahn & Buttgereit Nat Clin Pract Rheumatol. 2008; Hardy et al, Nat Rev Rheum. 2020)

6. The following figure illustrates the above information. It highlights important mechanisms by which glucocorticoids lead to attenuation of inflammation-induced bone resorption and thereby may compensate - at least in part - for its detrimental effects on bone mineral density in patients with rheumatoid arthritis.
7. This overall assessment is considered the current and state-of-the-art view as is evidenced by the following examples (selection of review articles, each citing respective original articles):

a. “Prior and current exposure to glucocorticoids increases the risk of fracture and bone loss. A key point is that the underlying inflammation for which glucocorticoids are used also plays a role in bone fragility, as there is a strong relationship between inflammatory cells and bone cells. Rheumatoid arthritis doubles the risk of hip and vertebral fractures regardless of the use of glucocorticoids.” (Dougdados, Curr Opin Rheumatol 2016)

b. “However, also the underlying inflammatory rheumatic disease is associated with the increased bone loss and fracture risk due to the chronic inflammation itself, and due to disability/immobility caused by active disease or joint destruction. The rapid and strong anti-inflammatory effect of GCs in patients with rheumatoid arthritis seem to balance the negative effects of GCs on bone in the early, active phase of the disease.” (Güler-Yüksel et al. Calcified Tissue International 2018)

c. “In fact, treatment of chronic inflammatory disease with glucocorticoids may have a beneficial effect on bone in some cases.” (Epsley et al. Front Physiol, 2021)

d. “Regarding therapeutic agents for RA, GC therapy deserves a special mention. Indeed, GCs suppress osteoblast bone formation, which is associated with a rapid suppression of procollagen type 1 N-terminal pro-peptide (PINP, a biomarker of bone formation), leading to an early reduction in trabecular bone. Interestingly, GCs also suppress osteoclast activity, certainly increased in active arthritis patients, which might have a protective effect in some cases. In fact, some studies show that GC use in RA could even be beneficial, with a low impact on BMD due to their anti-inflammatory and suppressive effect on arthritis activity.
Therefore, low doses of GCs could provide protection from inflammatory bone loss during polyarthritis flares and might counteract their unfavorable effects on bone resorption leading to neutral or even positive net skeletal balance). The cumulative GC dose (long-term or high dose) as well as the continuous vs. alternative GC dosage strategy are correlated with an increased risk of fracture or a reduced BMD in juxta-articular bone, spine and femoral neck. In addition, GCs induce muscle wasting which secondarily increases the risk of falls and fractures. However, a daily dose below 5 mg may have a relatively small impact on BMD in RA patients.” (Llorente et al. Front Med, 2021)
Supplemental Box S2

Indication for osteoporosis screening in this patient population were according to the German Osteoporosis Guidelines as provided by the Dachverband Osteologie (DVO): https://dv-osteologie.org/osteoporose-leitlinien

Here is short and focused summary of the screening rules:

Screening is recommended by the DVO if the estimated 10-year risk for vertebral and femoral fractures is 20% or higher (or was as high in the past two years). This includes both males and females regardless of age and is applicable also if the structured screening is expected to yield a therapeutic consequence.

Generally, all men above 80 years and women above 70 years are recommended to undergo an osteoporosis screening. Furthermore, all patients from the age of 50 years onwards with a history of fragility fractures or a glucocorticoid therapy with a daily dose of ≥7.5 mg per day for 3 months or longer.

The guideline also recommends a structured osteoporosis screening in postmenopausal women (≥ 50 years of age) and men (≥ 60 years) with following risk factors:

Use of medications linked with osteoporosis (oral glucocorticoids >2.5 mg/day for more than 3 months, proton pump inhibitors, opioids, anti-epileptic drugs, antidepressants, inhaled glucocorticoids, aromatase-inhibitors and medications linked to a higher risk of falls)

- low impact vertebral fracture (Genant 2°) or multiple vertebral fractures (Genant 1°)
- clinically relevant low-impact vertebral fracture
- low-impact non-vertebral fractures
- rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematoses
- father or mother with a history of femoral fractures
- endocrine diseases such as hyperthyroidisms, hypogonadism, diabetes type 1 or 2, factitious hyperthyroidism, (sub-)clinical hyperthyroidisms, Cushing syndrome
- neurologic/psychiatric diseases such as epilepsies, depression and others
- other diseases like heart failure
- active smoking or alcohol consumption